Pulse Steroids in Henoch-Schönlein Purpura
Pulse steroids are indicated for severe Henoch-Schönlein purpura nephritis, specifically when patients present with nephrotic syndrome, rapidly progressive crescentic disease (>50% crescents on biopsy), or deteriorating renal function.
Treatment Algorithm Based on Disease Severity
For HSP Without Nephritis or Mild Nephritis
- Do NOT use pulse steroids to prevent nephritis 1. The KDIGO guidelines explicitly recommend against using corticosteroids to prevent HSP nephritis (1B recommendation) 1.
- Research confirms this: early corticosteroid therapy does not reduce the risk of developing nephritis 2, 3.
- For persistent proteinuria 0.5-1 g/day per 1.73 m² after ACE inhibitor/ARB trial, use a 6-month course of oral corticosteroids as per IgA nephropathy protocols 1.
For Moderate HSP Nephritis
- Proteinuria >1 g/day per 1.73 m² with preserved renal function (GFR >50 ml/min per 1.73 m²)
- Oral corticosteroids are the first-line approach 1
- Methylprednisolone pulse therapy shows superior efficacy compared to hydrocortisone for moderate disease 4
For Severe HSP Nephritis (WHERE PULSE STEROIDS ARE INDICATED)
Indications for pulse methylprednisolone:
- Crescentic HSP with >50% crescents on biopsy 1, 5
- Nephrotic syndrome with deteriorating kidney function 1
- Rapidly progressive renal deterioration 1
Specific pulse steroid protocol:
- Intravenous methylprednisolone 500-1000 mg/day for 3 consecutive days 5
- Followed by oral prednisone 0.5 mg/kg every other day for 3.5 months 5
- Treat analogous to ANCA vasculitis with crescentic disease 1
Evidence Quality and Nuances
The strongest guideline evidence comes from KDIGO 2012 1, which provides clear recommendations based on disease severity. The key distinction is:
- Prevention: Strong evidence (1B) against using steroids to prevent nephritis
- Treatment of established severe nephritis: Recommended (2D) when crescentic or rapidly progressive
The prospective study by 5 demonstrated that pulse methylprednisolone in severe HSP nephritis (≥50% crescents) resulted in clinical recovery in 27/38 patients (71%), with significant reduction in activity index on follow-up biopsies. This supports aggressive early treatment before crescents become fibrous.
Common Pitfalls to Avoid
Do not give pulse steroids prophylactically for abdominal pain or arthritis hoping to prevent nephritis—this is ineffective and exposes patients to unnecessary toxicity 2, 1.
Do not delay treatment in severe nephritis waiting for spontaneous resolution. While HSP is self-limiting in 94% of children 6, those with nephrotic/nephritic features have 20% risk of permanent renal injury.
Do not use pulse steroids for mild proteinuria (<1 g/day)—ACE inhibitors/ARBs are first-line 1.
Obtain renal biopsy before initiating pulse steroids in unclear cases to confirm crescentic disease and guide intensity of therapy 1.
Steroid-Dependent or Refractory Disease
For chronic steroid-dependent HSP refractory to standard immunosuppression, rituximab has emerged as an effective alternative, reducing hospitalizations and allowing corticosteroid discontinuation 7. This should be considered before prolonged high-dose steroid exposure.